Media

Media

filter by theme
WOMEN's HEALTH
ENDOCRINOLOGY
Cell therapy
CORPORATE
REGULATORY

November 2012

23

HRA Pharma announce adrenocortical carcinoma award winners at ENS@T 2012 meeting

September 2012

04

HRA Pharma to exceed €50 million turnover in 2012 as ellaOne made available in over 50 countries worldwide

June 2012

11

Richter and HRA Pharma Expand their Marketing Agreement for Esmya® to Latin America

Février 2012

27

Uliprisrtal Acetate Granted European Marketing Authorisation for the Treatment of Symptoms Of Uterine Fibroids

Février 2012

02

NEJM Features Two Positive Pivotal Trials of HRA Pharma Compound Ulipristal Acetate for the Treatment of Uterine Fibroids

December 2011

16

HRA Pharma’s partner, Preglem, the wholly owned subsidiary of Gedeon Richter Plc., receives positive CHMP opinion for uterine fibroids treatment.

December 2011

05

HRA Pharma grants Richter marketing rights for Esmya for China, Russia and other CIS republics

November 2011

17

Riverside provides growth capital to France's HRA Pharma

filter by theme
WOMEN's HEALTH
ENDOCRINOLOGY
Cell therapy
CORPORATE
REGULATORY
closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?